Ultromics Raises $55M in Series C

Ultromics has successfully raised $55M in a Series C at a $300M valuation led by Optum Ventures, Oxford Science Enterprises.

Company Overview

Ultromics is a HealthTech company headquartered in Oxford, UK, founded in 2017 with 120+ employees.

AI for cardiac imaging

Fundraising Details

Amount Raised: $55M
Round Type: Series C
Valuation: $300M
Date: 2025-01-01
Investors: Optum Ventures, Oxford Science Enterprises

About Ultromics

AI for cardiac imaging The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.

Key Information

Headquarters: Oxford, UK
Founded: 2017
Team Size: 120+
Industry: HealthTech

What This Means

This funding round demonstrates strong investor confidence in Ultromics's vision and execution. The capital will likely be used to:

Scale Operations: Expand the team and operational capacity
Product Development: Enhance existing products and develop new features
Market Expansion: Enter new markets and strengthen presence in existing ones
Technology Investment: Invest in infrastructure and technology capabilities

Industry Context

The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Ultromics's successful fundraising reflects the strong fundamentals and growth potential in this space.

Valuation Milestone

Reaching a $300M valuation marks an important milestone for Ultromics, positioning the company among notable players in the HealthTech industry.

Looking Ahead

With this new capital, Ultromics is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.

This fundraising news was reported on 2025-01-01. For more information about Ultromics, visit their headquarters at Oxford, UK.